2023 World Conference on Lung Cancer (Posters)-P2.09. Safety and Efficacy of Aumolertinib in Patients with advanced NSCLC Harboring Uncommon EGFR Mutations: Cohort 2 Updated

P2.09. Safety and Efficacy of Aumolertinib in Patients with advanced NSCLC Harboring Uncommon EGFR Mutations: Cohort 2 Updated - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to evaluate the safety and efficacy of Aumolertinib treatment in patients with advanced non-small cell lung cancer (NSCLC) who had uncommon epidermal growth factor receptor (EGFR) mutations. The study included 17 patients who were treated with high-dose Aumolertinib. The results showed promising antitumor activity with manageable toxicity. The overall response rate (ORR) was 47.1%, disease control rate (DCR) was 100%, and the median progression-free survival (PFS) was 11.8 months. Subgroup analysis showed that the ORR was 50% in patients with G719X&L861Q&S768I genotype and 33.3% in patients with other genotypes. Tumor shrinkage was observed in 12 patients. No new safety signals or concerns were identified.<br /><br />The study aimed to address the poor efficacy of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in patients with NSCLC and uncommon EGFR mutations. A previous study had already reported the safety and efficacy of high-dose Aumolertinib in these patients, and this update provides additional data from cohort 2. The study included patients with non-squamous NSCLC in stage IIIB to IV, with confirmed uncommon EGFR mutations other than 19 Del and L858R. Asymptomatic CNS metastases were allowed. The primary endpoint was safety, and secondary endpoints included ORR, PFS, overall survival (OS), disease control rate (DCR), and duration of response (DOR).<br /><br />The study findings suggest that Aumolertinib treatment has promising antitumor activity and manageable toxicity in patients with advanced NSCLC and uncommon EGFR mutations. Further research is needed to evaluate the long-term efficacy and overall survival outcomes.

Asset Subtitle

Wen Fang

Meta Tag

Speaker Wen Fang

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

Aumolertinib treatment

advanced non-small cell lung cancer

NSCLC

uncommon epidermal growth factor receptor mutations

antitumor activity

toxicity

overall response rate

disease control rate

progression-free survival

EGFR-tyrosine kinase inhibitors